Oxy-inflammation in hyperbaric oxygen therapy applications

Early human evidence such as case series or small samples is exploring possible benefits.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Hyperbaric Oxygen Therapy (HBOT) is a non-invasive method of O2 delivery that induces systemic hyperoxia. Hyperbaric chamber consists of a pressure vessel and a compressed breathing gas supply, which can regulate internal pressure. The chamber delivers 100% O2 to patients according to predetermined protocols and is monitored by trained personnel. HBOT relies on increasing the inspired O2 fraction (fiO2) and elevating the partial pressure of O2 (pO2). O2 is typically administered at pressures between 1.5 and 3.0 ATA for 60 to 120 minutes, depending on the clinical presentation. Currently, there are 15 indications for HBOT approved by the Undersea and Hyperbaric Medicine Society, categorized into three groups: emergency medicine, wound healing acceleration, and antimicrobial effects. The present narrative review aims to elucidate the mechanisms action underlying HBOT, particularly oxy-inflammation, in various pathologies within these categories.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.